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A Ab bs st tr ra ac ct t
B Ba ac ck kg gr ro ou un nd d: Women’s Health Initiative randomized trials of postmenopausal hormone therapy
reported intervention effects on several clinical outcomes, with some important differences
between estrogen alone and estrogen plus progestin. The biologic mechanisms underlying these
effects, and these differences, have yet to be fully elucidated.
M Me et th ho od ds s: Baseline serum samples were compared with samples drawn 1 year later for 50 women
assigned to active hormone therapy in both the estrogen-plus-progestin and estrogen-alone
randomized trials, by applying an in-depth proteomic discovery platform to serum pools from 10
women per pool.
R Re es su ul lt ts s: In total, 378 proteins were quantified in two or more of the 10 pooled serum
comparisons, by using strict identification criteria. Of these, 169 (44.7%) showed evidence
(nominal P < 0.05) of change in concentration between baseline and 1 year for one or both of
estrogen-plus-progestin and estrogen-alone groups. Quantitative changes were highly correlated
between the two hormone-therapy preparations. A total of 98 proteins had false discovery rates
<0.05 for change with estrogen plus progestin, compared with 94 for estrogen alone. Of these,
84 had false discovery rates <0.05 for both preparations. The observed changes included multiple
proteins relevant to coagulation, inflammation, immune response, metabolism, cell adhesion,
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Postmenopausal hormone therapy was shown to have
multiple effects of public-health importance in the Women’s
Health Initiative (WHI) randomized, placebo-controlled
hormone-therapy trials of 0.625 mg/day conjugated equine
estrogen (E-alone) [1] or of this same estrogenic preparation
plus 2.5 mg/day medroxyprogesterone acetate (E+P) [2],
over respective average intervention periods of 7.1 and
5.6 years. The observed effects were similar for the two
preparations for some outcomes, including stroke [3,4] and
hip fracture [5,6]; whereas E+P effects were unfavorable
(P < 0.05) compared with those for E-alone for other out-
comes, including coronary heart disease (CHD) [7,8], breast
cancer [9,10], and venous thromboembolism (VT) [11,12],
and a global index [1,2] that was designed to summarize
major health benefits versus risks [13].
Several of the articles just cited formally examined whether
interactions occurred between the hormone-therapy hazard
ratios and baseline study-subject characteristics. Although
some moderate variations were detected (for example, for
E-alone and breast cancer [10]), these tended to provide
limited insight into the biologic mechanisms and pathways
involved in the observed clinical effects. A cardiovascular
disease nested case-control study also was conducted to
relate baseline values of candidate biomarkers and post-
randomization biomarker changes to observed hormone-
therapy effects. This study confirmed baseline biomarker
disease associations and identified some pertinent bio-
marker changes after hormone-therapy initiation, but
identified few interactive or explanatory biomarkers for
either CHD [14] or stroke [15], although the E+P hazard
ratio elevation for CHD appeared to be smaller among
women having relatively low baseline low-density lipo-
protein cholesterol [14].
It follows that much remains to be explained about the
pattern of biologic changes induced by these hormone-therapy
preparations in relation to the outcome effects mentioned
earlier. Proteomic discovery work has the potential to
identify biomarkers that may help to explain E+P or E-alone
clinical effects or differences in effects between the two
preparations. Hence, we applied a comprehensive quanti-
tative proteomic approach designated Intact Protein
Analysis System (IPAS) [16-19] to compare the serum
proteome at 1 year after randomization to baseline for
50 women assigned to E+P and for 50 women assigned to
E-alone, in the WHI hormone-therapy trials. These women
were selected to be free of major disease outcomes through
the WHI clinical trial intervention phase and were selected
to be adherent to their assigned hormone regimen over the
first year of treatment, but were otherwise randomly selected
from women assigned to active treatment in the trial
cohorts. The IPAS approach involves extensive fractionation
followed by tandem mass spectrometry and is capable of
identifying proteins over seven orders of abundance. For
reasons of throughput, serum pools were formed from
10 E+P women (five baseline and five 1-year pools), or from
10 E-alone women, before proteomic analysis.
We recently reported [20] proteomic changes from the
E-alone component of this project. An impressive 10.5% of
proteins had false discovery rates, for a change, of <0.05.
The affected proteins had relevance to multiple pathways,
including coagulation, metabolism, osteogenesis, and
inflammation, among others. Ten of 14 protein changes
tested were confirmed with enzyme-linked immunosorbent
assays (ELISAs) in the original samples, and in serum
samples from 50 nonoverlapping randomly chosen women,
selected by using the same criteria, from the E-alone trial
treatment group.
Here, we sought to uncover proteins and pathways that are
differentially affected by E+P therapy relative to E-alone that
would provide leads for the comparatively unfavorable
effects with E+P observed in these trials.
M Me et th ho od ds s
S St tu ud dy y   c co oh ho or rt ts s
The use of human samples was approved by the Fred
Hutchinson Cancer Research Center Institutional Review
Board. Fifty study subjects were randomly selected from the
8,506 women assigned to active E+P in the WHI clinical
trial, which also included 8,102 women assigned to placebo.
All women were postmenopausal, with a uterus, and in the
age range from 50 to 79 years, at recruitment during 1993
through 1998. The selected women were required to have
been adherent to study medication (80% or more of pills
taken) over the first year after randomization, and without a
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growth factors, and osteogenesis. Evidence of differential changes also was noted between the
hormone preparations, with the strongest evidence in growth factor and inflammation pathways.
C Co on nc cl lu us si io on ns s: Serum proteomic analyses yielded a large number of proteins similarly affected by
estrogen plus progestin and by estrogen alone and identified some proteins and pathways that
appear to be differentially affected between the two hormone preparations; this may explain their
distinct clinical effects.major clinical event (CHD, stroke, VT, breast or colorectal
cancer, or hip fracture) over the intervention and follow-up
period (through March 2005). A second nonoverlapping
subset of E+P women was selected, by using the same
criteria, for replication studies with ELISA. As previously
reported [20], the same selection criteria were used for the
E-alone discovery and replication phases of the study.
Women enrolled in the E-alone trial (10,739) satisfied the
same eligibility criteria as E+P enrollees, but were post-
hysterectomy at randomization. Women who used hormone
therapy before trial enrollment had mostly stopped such
treatment, months or years before enrollment, and were
otherwise required to undergo a 3-month washout before
randomization. Serum samples, collected at baseline and
1 year, were stored at -80° C until proteomic analyses.
S Sa am mp pl le e   p pr re ep pa ar ra at ti io on n, ,   p pr ro ot te ei in n   f fr ra ac ct ti io on na at ti io on n, ,   a an nd d   m ma as ss s
s sp pe ec ct tr ro om me et tr ry y   a an na al ly ys si is s
These methods were previously described [20] in detail and
are only briefly summarized here. As in the E-alone project
component, pools formed from 30 µl of serum for 10
randomly selected women from the 50 E+P group women
were formed from baseline and 1-year specimens.
After immunodepletion of the six most abundant proteins
(albumin, IgG, IgA, transferrin, haptoglobin, and anti-
trypsin), pools were concentrated, and intact proteins having
cysteine residues were isotopically labeled with acrylamide
(baseline pools received the ‘light’ C12 acrylamide; 1-year
pools the ‘heavy’ C13 acrylamide). The baseline and 1-year
pools were than mixed together for further analysis.
The combined sample was diluted, and each sample was
separated into 12 subsamples by using anion exchange
chromatography, and each subsample was further separated
into 60 fractions by using reversed-phase chromatography,
giving a total of 720 fractions for each original mixed
sample. Aliquots of 200 µl from each fraction, corres-
ponding to about 200 µg of protein, were separated for mass
spectrometry ‘shotgun’ analysis.
Lyophilized aliquots from the 720 individual fractions were
subjected to in-solution trypsin digestion, and individual
digested fractions, four to 60 from each reversed-phase run,
were combined into 11 pools, giving a total of 132 (12 × 11)
fractions for analysis from each original mixed baseline and
1-year pool. Tryptic peptides were analyzed with an LTQ-FT
mass spectrometer. Spectra were acquired in a data-depen-
dent mode in a mass/charge range of 400 to 1,800, and the
five most abundant +2 or +3 ions were selected from each
spectrum for tandem mass spectrometry (MS/MS) analysis.
P Pr ro ot te ei in n   i id de en nt ti if fi ic ca at ti io on n   a an nd d   b ba as se el li in ne e   v ve er rs su us s   1 1- -y ye ea ar r   c co on nc ce en nt tr ra at ti io on n
a as ss se es ss sm me en nt t
The acquired LC-MS/MS data were automatically processed
by the Computational Proteomics Analysis System [21].
Database searches were performed by using X!Tandem
against the human International Protein Index (IPI) by
using tryptic search. Database search results were analyzed
by using PeptideProphet [22] and ProteinProphet [23].
The relative quantitation of 1-year to baseline concentration
for cysteine-containing peptides identified by MS/MS was
extracted by using a script designated Q3 ProteinRatioParser
[16], which calculates the relative peak areas of heavy to light
acrylamide-labeled peptides. Peaks with zero area were reset
to a background value to avoid singularities. Peptides having
PeptideProphet  ≥0.75, Tandem expect score <0.10, and
mass deviation <20 ppm were considered for quantification.
Proteins were identified as those having ProteinProphet
scores ≥0.90, and their ratios were calculated by taking the
geometric mean of all the associated peptide ratios. Proteins
from all 10 IPAS experiments were aligned by their protein
group number, assigned by ProteinProphet, to identify
master groups of indistinguishable proteins across experi-
ments. Ratios for these protein groups were logarithmically
transformed and median-centered at zero. The following
protein groups were removed in this analysis: groups that
had fewer than five peptide ratios across all 10 experiments;
groups that contained proteins that were targeted for
depletion; and groups in which all proteins had been
annotated as ‘defunct’ by IPI.
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s   o of f   1 1- -y ye ea ar r   v ve er rs su us s   b ba as se el li in ne e   p pr ro ot te ei in n
c co on nc ce en nt tr ra at ti io on ns s
Protein log-(concentration) ratios were analyzed by first
normalizing further, so that the median of the log-ratios is
zero for all the proteins identified from a mixed baseline and
1-year sample. Concentration changes after E+P use were
identified by testing the hypothesis that the mean of the log-
ratios across the (up to 5) mixed samples is zero, by using a
weighted moderated t statistic [24] implemented in the R
package LIMMA [25]: the log-ratios were weighted by the
number of quantified peptides for each protein, and a matrix
of weights was included in the linear model. The variance
was estimated by using the sum of the sample variances from
the E+P and E-alone data, with the requirement of at least one
degree of freedom for variance estimation. Benjamini and
Hochberg’s method [26] was used to accommodate multiple
testing for the large number of proteins quantified, through
the calculation of estimated false discovery rates (FDRs).
The same method was used to identify proteins for which the
1-year to baseline change in concentration differed between
E+P and E-alone. Specifically, a moderated t statistic was
used to test for a difference in means between the log-ratios
for E+P and those for E-alone, with common log-ratio
variance for the two preparations.
B Bi io ol lo og gi ic c   p pa at th hw wa ay y   a an na al ly ys si is s
We developed a regularized Hotelling T2 procedure (Chen
LS, Prentice RL, and Wang P, submitted for publication,
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pathways, that change concentration with E+P, or that
change differentially in the E+P and E-alone project compo-
nents. This testing procedure takes advantage of the
correlation structure among the log-ratios for proteins in a
given set. Protein sets were defined by using the KEGG
database [27,28].
To accommodate multiple hypotheses testing issues, the
significance for individual proteins or for biologic pathways,
is based on a 5% FDR criterion.
E EL LI IS SA A- -b ba as se ed d   v va al li id da at ti io on n
ELISAs are commercially available for some of the proteins
for which evidence emerged of change after E+P use, or of
differential change between E+P and E-alone. ELISA tests
were applied according to manufacturer’s protocols for
individual baseline and 1-year serum samples from an
additional randomly selected nonoverlapping 50 E+P and 50
E-alone women, for independent validation of leads from the
proteomic discovery work. P values were obtained by
applying t tests to log-transformed 1-year-to-baseline concen-
tration ratios. Log-ratios from ELISA and IPAS were
compared to assess discovery platform signals.
R Re es su ul lt ts s
The average age at enrollment for the selected 50 E+P
women is 63.2, similar to that for the trial cohort as a whole.
Other study-subject characteristics were generally similar
also to those for the entire trial cohort [2], as was also the
case for the 50 selected E-alone women [20]. Subject
characteristics for both studies are shown in Table 1. Some
characteristics varied among the pools of size 10, as expected
with the random assignment of women to pools. For
example, the average baseline age (standard deviation) for
the five E+P pools was 60.6 (8.4), 65.8 (5.3), 63.5 (8.5), 63.2
(7.1), and 62.8 (7.0), respectively. The project generated
2,576,869 spectra from the E+P pools, as compared with
2,458,506 from the E-alone pools. These led to the identifi-
cation of 3,669 IPI-based proteins from the E+P pools
compared with 4,679 from the E-alone analyses; and 942
IPI-based relative protein concentrations for E+P, versus
1,054 for E-alone, including 698 that were quantified in both
E+P and E-alone analyses.
S Se er ru um m   p pr ro ot te ei in n   c co on nc ce en nt tr ra at ti io on n   r ra at ti io os s
Protein concentration ratios were further filtered and curated
by using stringent standards (see Methods) for protein
identification, including a requirement that a protein is
quantified in at least two of the 10 IPAS experiments leading
to a focus on 378 proteins (IPIs), all but 10 of which were
quantified for both E+P and E-alone. A remarkable 169
(44.7%) of these showed evidence (nominal P < 0.05) of
change from baseline to 1-year with E+P or E-alone, or with
both. For E+P, 371 proteins were quantified under these
quality standards, of which 132 (35.6%) had P < 0.05 as
compared with 18.6 expected by chance, and 98 (26.4%) had
FDRs <0.05 compared with 94 for E-alone. Of these, 84 had
FDR <0.05 for both preparations. Table S1 in Additional
file 1 shows estimated 1-year-to-baseline concentration log
ratios for all 378 proteins ranked according to the minimum
of  P values for change with E+P or change with E-alone.
Significance levels (P  values) are also given for a test of
equality of the E+P and E-alone ratios.
Table 2 lists proteins for which strong evidence (FDR < 0.01)
exists of changed concentration with E+P or with E-alone,
according to biologic pathways that were found to be
associated with E-alone use in [20]. Nominal P values and
FDRs for change also are provided. Of note, five proteins
involved in the insulin growth factor pathway are repre-
sented in Table 2. Five of these proteins have 1.25-fold or
greater changes in their concentrations with E-alone or E+P
treatment or both. Protein NOV homologue (NOV) and
insulin-like growth factor 1 (IGF1) were both decreased with
E-alone and E+P. Insulin-like growth factor-binding protein 1
(IGFBP1) level was increased with both E-alone and E+P.
Strong evidence of the E+P effect exists on each of blood
coagulation and inflammation, metabolism, osteogenesis,
complement and immune response, and cell adhesion. More-
over, the changes (base 2 logarithm of 1-year-to-baseline
concentration ratio in Table 2) are mostly quantitatively very
similar between E+P and E-alone, attesting to major effects
of conjugated equine estrogens on the serum proteome.
Table 3 presents the differences in quantitative ratios for
E+P minus E-alone that were nominally significantly differ-
ent (P < 0.05) from each other. For this analysis, we tested
the 368 proteins meeting our identification and quantifi-
cation criteria that were common to both E+P and E-alone.
Twenty-six proteins were identified with nominal P values
<0.05 for differential change between E+P and E-alone. The
list includes proteins involved in insulin growth factor
binding and inflammation. Insulin growth factor-binding
proteins (IGFBPs) may be affected differently by E+P
compared with E-alone. Specifically, three proteins show
nominally statistically significant differences with E+P
compared with E-alone. IGFBP1 is increased (log2 ratio,
1.27) with E-alone, but the increase is mitigated with E+P
(log2 ratio, 0.528). IGFBP4 is increased with E-alone (log2
ratio, 0.511), but not with E+P (log ratio, 0.179). NOV, also
known as IGFBP9, is decreased with E-alone (log2 ratio, -
0.344) and decreased to a greater extent with E+P (log2
ratio, -0.759).
P Pr ro ot te ei in n- -s se et t   a an na al ly ys se es s
In addition to the protein classifications presented earlier,
the 368 proteins quantified for both E+P and E-alone were
subjected to protein set analysis. In total, 41 KEGG human
disease pathways were represented by at least two proteins
in this group. Each protein has been quantified in at least
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T Ta ab bl le e   1 1
B Ba as se el li in ne e   c ch ha ar ra ac ct te er ri is st ti ic cs s   a am mo on ng g   w wo om me en n   i in nc cl lu ud de ed d   i in n   h ho or rm mo on ne e- -t th he er ra ap py y   p pr ro ot te eo om mi ic cs s   p pr ro oj je ec ct t   ( (n n = =   5 50 0   f fo or r   E E+ +P P   a an nd d   f fo or r   E E- -a al lo on ne e   t tr ri ia al ls s) )
E+P E-alone
Number % Number % P valuea
Age group at screening, years 0.20
50-59 17 34.0 25 50.0
60-69 21 42.0 13 26.0
70-79 12 24.0 12 24.0
Minority race/ethnicity 3 6.0 8 16.0 0.20
Postmenopausal hormone therapy use 0.69
Never used 31 62.0 26 52.0
Past user 15 30.0 19 38.0
Current user (3-month ‘wash out’ before enrollment) 4 8.0 5 10.0
Smoking 0.50
Never 34 69.4 29 58.0
Past 14 28.6 19 38.0
Current 1 2.0 2 4.0
Parity 0.74
Never pregnant/no term pregnancy 6 12.0 4 8.0
≥1 term pregnancy 44 88.0 46 92.0
Age at first birth, years 0.38
<20 8 21.1 15 34.1
20-29 29 76.3 27 61.4
30+ 1 2.6 2 4.5
Treated diabetes 2 4.0 7 14.0 0.16
Treated for hypertension or BP ≥140/90 15 31.9 17 37.0 0.67
History of high cholesterol requiring pills 2 4.3 2 4.5 >0.99
Statin use at baseline 0 0.0 2 4.0 0.49
Aspirin (≥80 mg) use at baseline 8 16.0 8 16.0 >0.99
History of MI 1 2.0 0 0.0 >0.99
History of angina 1 2.0 3 6.0 0.62
History of CABG/PTCA 1 2.0 0 0.0 >0.99
History of DVT or PE 1 2.0 0 0.0 >0.99
Family history of breast cancer (female) 6 13.0 7 14.6 >0.99
History of fracture on or after age 55 3 8.3 1 3.1 0.62
Gail Model Five Year Risk of Breast Cancer 0.26
<1 7 14.0 10 20.0
1 - <2 31 62.0 34 68.0
2 - <5 12 24.0 6 12.0
Number of falls in last 12 months 0.97
None 31 66.0 30 69.8
1 time 9 19.1 7 16.3
2 times 6 12.8 6 14.0
3 or more times 1 2.1 0 0.0
Mean SD Mean SD P valueb
Age at screening, years 63.2 7.2 61.4 7.9 0.24
Body-mass index (BMI), kg/m2 28.8 6.0 31.1 6.1 0.05
a aP value based on Fisher’s Exact test of association. bP value based on two-sample t test. MI = myocardial infarction; CABG/PCTA = coronary artery
bypass graft/percutaneous transluminal angiography; DVT = deep vein thrombosis; PE = pulmonary embolus.http://genomemedicine.com/content/1/12/121 Genome Medicine 2009, Volume 1, Issue 12, Article 121 Pitteri et al. 121.6
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T Ta ab bl le e   2 2
G Ge en ne e   o on nt to ol lo og gy y   c cl la as ss si if fi ic ca at ti io on n   o of f   p pr ro ot te ei in ns s   w wi it th h   s st ta at ti is st ti ic ca al ll ly y   s si ig gn ni if fi ic ca an nt t   c ch ha an ng ge es s   ( (F FD DR R   < <   0 0. .0 01 1) )   f fo or r   E E+ +P P   o or r   E E- -a al lo on ne e
E+P E-Alone
Log2 ratio Log2 ratio 
year 1  year 1 
relative to  relative to 
Protein Description baseline P value FDR baseline P value FDR
Blood coagulation and inflammation
VTN Vitronectin 0.352 2.16E-07 2.68E-05 0.368 7.09E-08 8.98E-06
CP Ceruloplasmin 0.679 5.19E-07 2.87E-05 0.752 3.01E-07 2.86E-05
SERPINC1 Antithrombin III variant -0.196 5.05E-06 0.000157 -0.143 5.50E-05 0.00106
PLG Plasminogen 0.224 1.56E-05 0.000404 0.230 1.24E-05 0.000393
HABP2 Uncharacterized protein 0.251 5.23E-05 0.00108 0.309 7.24E-05 0.00131
F12 Coagulation factor XII 0.261 0.000102 0.00158 0.252 0.000219 0.00268
APOH β2-Glycoprotein 1 0.149 0.000199 0.00242 0.193 8.89E-05 0.00135
ATRN Attractin -0.190 0.000213 0.00242 -0.126 0.00366 0.0214
F9 Coagulation factor IX 0.540 0.000214 0.00242 0.572 0.000511 0.00498
TFPI Tissue factor pathway inhibitor -0.396 0.000315 0.00317 -0.369 8.49E-05 0.00135
KNG1 Kininogen-1 0.152 0.00106 0.00786 0.228 5.60E-05 0.00106
Metabolism
GC Vitamin D-binding protein 0.231 3.10E-06 0.000115 0.237 2.75E-06 0.000131
HPX Hemopexin 0.123 6.65E-05 0.00118 0.117 0.000124 0.00162
RBP4 Plasma retinol-binding protein 0.167 0.000117 0.00161 0.177 0.000262 0.00311
APOA2 Apolipoprotein A-II 0.212 0.000532 0.00483 0.302 1.75E-05 0.000475
ENPP2 Ectonucleotide Pyrophosphatase/ 0.369 0.00692 0.0333 0.650 0.000749 0.00619
phosphodiesterase family member 2
Osteogenesis
FETUB Fetuin-B 0.783 1.09E-09 4.04E-07 0.741 1.02E-09 3.89E-07
COL1A1 Collagen α-1(I) chain -0.896 5.40E-07 2.87E-05 -0.575 8.80E-05 0.00135
AHSG α2-HS-glycoprotein 0.211 3.44E-06 0.000116 0.243 7.46E-07 5.02E-05
NOTCH2 Neurogenic locus notch  -0.784 0.000315 0.00317 -0.062 0.648 0.815
homologue protein 2
Complement and immune response
PGLYRP2 N-acetylmuramoyl-L-alanine amidase -0.343 1.49E-06 6.17E-05 -0.335 3.72E-06 0.000141
ORM2 α1-acid glycoprotein 2 -0.181 1.63E-05 0.000404 -0.144 8.38E-05 0.00135
C4BPA C4B-binding protein α chain -0.200 3.34E-05 0.000731 -0.148 0.000377 0.00398
CFHR1 Complement factor H-related protein 1 0.162 8.95E-05 0.00145 0.185 2.96E-05 0.000661
CFB Complement factor B 0.137 0.000106 0.00158 0.210 5.58E-06 0.000193
C8A Complement component C8 α chain -0.206 0.000163 0.00216 -0.202 0.000121 0.00162
C4BPB C4B-binding protein β chain -0.260 0.00018 0.0023 -0.196 0.00156 0.0112
PGLYRP1 Peptidoglycan recognition protein 0.321 0.000232 0.00253 -0.056 0.458 0.68
CFHR5 Complement factor H-related 5 0.179 0.000264 0.00281 0.241 2.76E-05 0.000656
MASP2 Mannan-binding lectin serine protease 2 0.200 0.000435 0.00415 0.173 0.000643 0.00568
CFHR2 Complement factor H-related protein 2 0.181 0.000449 0.00417 0.205 0.00016 0.00203
C8B Complement component C8 β chain -0.221 0.00059 0.00522 -0.199 0.0015 0.0112
ITIH4 Inter-α-trypsin inhibitor heavy chain H4 0.458 0.000733 0.00634 0.374 0.00495 0.0273
VNN1 Pantetheinase 0.477 0.000888 0.00688 0.517 0.00124 0.00963
C6 complement component C6 -0.123 0.00151 0.011 -0.171 0.000123 0.00162
B2M β2-microglobulin 0.208 0.00205 0.0144 0.230 0.0011 0.00873
LRG1 Leucine-rich α2-glycoprotein 0.278 0.00553 0.0278 0.445 0.000582 0.0054
MBL2 Mannose-binding protein C -0.190 0.00677 0.0331 -0.341 9.37E-05 0.00137
Continued overleaftwo IPAS experiments in both E+P and E-alone. Table 4
indicates pathways that show a baseline versus 1-year
difference for E+P and E-Alone at FDR < 0.05 by using a
regularized Hotelling T2 test. We also tested the equality of
log-concentration ratios between the two regimens for
proteins in these pathways by using the same test statistic.
Two pathways had FDR < 0.05 (Table 5). The gonadotropin-
releasing hormone (GnRH) signaling pathway, known to be
regulated by estrogen, was represented by two proteins
(matrix metalloproteinase 2 (MMP2) and phospholipase A2
(PLA2G1B)), and a pathway associated with bladder cancer
was represented by three proteins (MMP2, thrombospondin 1
(THBS1), and vascular endothelial growth factor C (VEGFC)).
Both pathways had nominal P values of 0.002, with corres-
ponding FDRs of 0.041. MMP2, a collagenase with the
ability to break down extracellular matrix proteins, was
common to both pathways, and substantially explains the
difference between the two regimens for these pathways.
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G Ge en ne e   o on nt to ol lo og gy y   c cl la as ss si if fi ic ca at ti io on n   o of f   p pr ro ot te ei in ns s   w wi it th h   s st ta at ti is st ti ic ca al ll ly y   s si ig gn ni if fi ic ca an nt t   c ch ha an ng ge es s   ( (F FD DR R   < <   0 0. .0 01 1) )   f fo or r   E E+ +P P   o or r   E E- -a al lo on ne e
E+P E-Alone
Log2 ratio Log2 ratio 
year 1  year 1 
relative to  relative to 
Protein Description baseline P value FDR baseline P value FDR
Complement and immune response (Continued)
LILRA3 Leukocyte immunoglobulin-like  -0.237 0.00874 0.0374 -0.281 0.000277 0.00319
receptor subfamily A member 3
FN1 Fibronectin -0.193 0.0663 0.176 -0.358 0.000574 0.0054
Cell adhesion
ICAM1 Intercellular adhesion molecule 1 -0.299 2.69E-05 0.000626 -0.142 0.00171 0.012
MEGF10 Multiple epidermal growth  -1.330 0.0365 0.114 -1.100 0.000671 0.0058
factor-like domains 10
Growth factor activity
IGFBP7 Insulin-like growth factor-binding  -0.295 0.000404 0.00395 -0.133 0.0342 0.109
protein 7
NOV Protein NOV homologue -0.759 0.00083 0.00672 -0.344 0.0123 0.0506
IGF1 Insulin-like growth factor IA -0.353 0.000981 0.00745 -0.371 0.000403 0.00414
IGFBP1 Insulin-like growth factor-binding  0.528 0.00242 0.0158 1.270 3.66E-06 0.000141
protein 1
IGFBP4 Insulin-like growth factor-binding  0.179 0.102 0.234 0.511 0.000697 0.00588
protein 4
Other
SHBG Sex hormone-binding globulin 1.460 1.14E-08 2.13E-06 1.450 2.57E-08 4.88E-06
AGT Angiotensinogen 1.150 3.09E-07 2.87E-05 1.200 2.05E-06 0.000111
LUM Lumican -0.382 4.81E-07 2.87E-05 -0.163 0.00175 0.0121
TFF3 Trefoil factor 3 2.590 8.84E-07 4.11E-05 2.160 2.06E-05 0.000522
OAF Out at first protein homologue 0.398 7.32E-06 0.000209 0.393 4.17E-05 0.000881
A1BG α1B-Glycoprotein 0.167 5.71E-05 0.00112 0.266 7.92E-07 5.02E-05
ABI3BP Target of NESH-SH3 -0.290 6.07E-05 0.00113 -0.184 0.00149 0.0112
CLEC3B Tetranectin -0.240 7.65E-05 0.00129 -0.158 0.00102 0.00827
FBN1 Fibrillin-1 -0.365 0.000114 0.00161 -0.269 1.45E-05 0.000423
DBH Dopamine β-hydroxylase -0.262 0.000207 0.00242 -0.186 0.00203 0.013
FGA Fibrinogen α chain 0.364 0.00076 0.00643 0.303 0.00741 0.0373
SPARCL1 SPARC-like protein 1 -0.311 0.0008 0.00661 -0.043 0.508 0.722
CPN2 Carboxypeptidase N subunit 2 0.161 0.000865 0.00685 0.190 0.000331 0.0036
AMBP AMBP protein 0.116 0.00283 0.0174 0.148 0.00061 0.00552
PEAR1 Platelet endothelial aggregation  -0.650 0.00948 0.0379 -0.722 0.000424 0.00424
receptor 1
AFM Afamin 0.058 0.119 0.259 0.177 0.00033 0.0036
P value = significance level for test of no change in protein concentration; FDR = estimated false discovery rate for this test.E EL LI IS SA A- -b ba as se ed d   p pr ro ot te ei in n   a as ss sa ay ys s   i in n   a an n   i in nd de ep pe en nd de en nt t   s se et t   o of f   s su ub bj je ec ct ts s
The 26 proteins with nominal P < 0.05 for differential change
between E+P and E-alone based on IPAS mass spectrometry
findings each had FDR > 0.3, so that many of these may be
attributable to chance. We sought to determine whether
concordant changes in these proteins can be demonstrated
in an independent set of subjects and with independent
methods. Figure 1 shows 1-year-to-baseline concentration
log-ratios (95% confidence intervals (CIs)) from IPAS mass
spectrometry data along with corresponding values from
ELISA evaluation of 1-year-to-baseline ratios for an indepen-
dent set of 50 women selected from the active-treatment
group in the E+P trial. Corresponding IPAS and ELISA
information also is provided for E-alone. We observed
concordance of IPAS and ELISA data between the two sets of
subjects for six of eight proteins assayed. The lack of
replication for ceruloplasmin (CP) and ICAM1 may be due to
multiple comparison effects in the discovery component or
other factors, notably distinct epitope targets by ELISA
assays compared with quantified peptides by mass
spectrometry.
D Di is sc cu us ss si io on n
These analyses show that 1 year of use of E+P has a profound
effect on the serum proteome, with more than a fourth
(26.4%) of quantified proteins having FDR < 0.05 for change.
Eight proteins with altered levels were further tested in an
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D Di if ff fe er re en nc ce e   i in n   Y Ye ea ar r   1 1   f fr ro om m   b ba as se el li in ne e   c co on nc ce en nt tr ra at ti io on n   r ra at ti io os s   ( (E E+ +P P   m mi in nu us s   E E- -A Al lo on ne e) )   f fo or r   a al ll l   p pr ro ot te ei in ns s   w wi it th h   d di if ff fe er re en nc ce e   o of f   P P < <   0 0. .0 05 5
Difference of log2 ratios (year 1 
Protein Description relative to baseline): E+P minus E-alone P-Diff FDR
LUM Lumican -0.219 0.00141 0.317
IGFBP1 Insulin-like growth factor-binding protein 1 -0.742 0.00227 0.317
PGLYRP1 Peptidoglycan recognition protein 0.377 0.00259 0.317
NOTCH2 Neurogenic locus notch homologue protein 2 -0.723 0.00426 0.33
ACTB Actin cytoplasmic 1 0.667 0.00527 0.33
LYVE1 Lymphatic vessel endothelial hyaluronic acid receptor 1 -0.217 0.00538 0.33
AZGP1 α2-Glycoprotein 1 zinc 0.496 0.00776 0.408
ICAM1 Intercellular adhesion molecule 1 -0.158 0.0126 0.511
SPARCL1 SPARC-like protein 1 -0.268 0.0138 0.511
COL1A1 Collagen α-1(I) chain -0.321 0.015 0.511
A1BG α1B-glycoprotein -0.099 0.0153 0.511
SEPP1 Selenoprotein P 0.756 0.0181 0.549
F5 Coagulation factor V 0.301 0.0194 0.549
CFL1 Cofilin-1 0.597 0.023 0.549
C6orf115 Similar to protein C6ORF115 1.070 0.0233 0.549
MMP2 72-kDa type IV collagenase 1.190 0.0246 0.549
HRG Histidine-rich glycoprotein -0.136 0.0282 0.549
ABCA9 ATP-binding cassette subfamily A member 9 3.280 0.0284 0.549
MMRN1 Multimerin-1 0.691 0.0293 0.549
AFM Afamin -0.120 0.0298 0.549
MCAM Cell-surface glycoprotein MUC18 -0.357 0.0409 0.614
NOV Protein NOV Homologue -0.415 0.0409 0.614
TFF2 Trefoil factor 2 -1.920 0.0412 0.614
ECM1 Extracellular matrix protein 1 -0.184 0.0412 0.614
IGFBP4 Insulin-like growth factor-binding protein 4 -0.332 0.0442 0.614
CFB Complement factor B  -0.073 0.0444 0.614
P-Diff = significance level for test of equality of protein-concentration ratios for E+P and E-alone; FDR = estimated false discovery rate for this test.independent set of samples. ELISA assays of six of the eight
proteins showed changes concordant with the mass spectro-
metry data. The correlation of initial concentration ratios by
mass spectrometry with ELISA ratios from an independent
set of samples supports the reliability of the protein changes
observed. Our previous report on E-alone [20] provided a
detailed discussion of the proteins that changed after
treatment with conjugated equine estrogens, in which 19% of
proteins were changed after 1 year of treatment. Findings for
10 proteins were confirmed and validated by ELISA assays.
Proteins altered with E-alone therapy had relevance to
processes such as coagulation, inflammation, growth factors,
osteogenesis, metabolism, and cell adhesion, among others.
The most striking feature of the present E+P analysis is the
similarity in these quantitative proteomic changes when
medroxyprogesterone acetate is added to the daily conju-
gated equine estrogen. For changes with E+P, 98 proteins
had FDR < 0.05 compared with 94 proteins for E-alone. Of
these, 84 proteins had FDR < 0.05 for both preparations,
and corresponding intensity ratios tended to be quite similar
between the two regimens for most of these proteins. Hence,
our prior discussion [20] of proteins and pathways that were
changed after E-alone is largely applicable to the E+P
hormone preparation as well. The 1 year of aging between
the baseline and 1-year blood-sample collection could have
some influence on the serum proteome, but any such
influence should be absent for the comparison of E+P versus
E-alone changes, because age-related changes would apply
equally for the two regimens.
When we specifically sought proteins for which the change
with E+P differed from that for E-alone, a number of
potential proteins (Table 3) emerged, but chance could not
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Number quantified protein P valuea FDR
E+P Pathway
Porphyrin and chlorophyll metabolism 2 <0.001 <0.001
Dorsoventral axis formation 4 <0.001 <0.001
Motor signaling pathway 2 0.002 0.009
Pancreatic cancer 2 0.002 0.009
Focal adhesion 14 0.003 0.011
Bladder cancer 3 0.005 0.015
Renal cell carcinoma 3 0.009 0.023
Notch signaling pathway 5 0.011 0.024
Ether lipid metabolism 2 0.012 0.024
Long term depression 2 0.022 0.039
Regulation of actin cytoskeleton 8 0.025 0.041
Cytokine-cytokine receptor interaction 21 0.032 0.048
E-alone pathway
Porphyrin and chlorophyll metabolism 2 <0.001 <0.001
GNRH signaling pathway 2 <0.001 <0.001
Ether lipid metabolism 2 0.001 0.011
Bladder cancer 3 0.002 0.016
aFrom a regularized Hotelling T2 test.
T Ta ab bl le e   5 5
K KE EG GG G   p pa at th hw wa ay ys s   h ha av vi in ng g   t tw wo o   o or r   m mo or re e   q qu ua an nt ti it ta at te ed d   p pr ro ot te ei in ns s   f fo or r   w wh hi ic ch h
e ev vi id de en nc ce e   o of f   d di if ff fe er re en nt ti ia al l   c ch ha an ng ge e   b be et tw we ee en n   E E+ +P P   a an nd d   E E- -a al lo on ne e   w wa as s   s si ig gn ni if fi ic ca an nt t, ,
w wi it th h   F FD DR R   < <   0 0. .0 05 5
E+P versus E-Alone GNRH signaling pathway Bladder cancer
Number of proteins 2 3
Proteins in the pathway MMP2, PLA2G1B MMP2, THBS
VEGFC
P valuea 0.002 0.002
FDRa 0.041 0.041
aFrom a regularized Hotelling T2 test.be ruled out as an explanation for any particular protein. To
check whether these suggested differences could be
attributable to differences in the E+P and E-alone study
cohorts (Table 1) we repeated the Table 3 analyses with the
mean age and mean BMI at baseline in each pool as
adjustment factors. The log intensity ratio differences were
not appreciably affected by this adjustment, although P
values tended to become less significant because of
reduction in ‘degrees of freedom’ for the moderated t tests.
Interestingly, after this adjustment, the FDR for NOTCH2
decreased to 0.02. None of the other FDRs in this sensitivity
analysis were <0.05. Aberrant NOTCH signaling has been
implicated in tumorigenesis and has been reported to play
an oncogenic role in breast cancer [29,30]. A decrease of
NOTCH2 serum levels with E+P, but not E-alone, could be
related to alteration of signaling and increased risk of breast
cancer with E+P but not with E-alone. A differential change
between E+P and E-alone in IGFBP1 was supported by
ELISA data in an independent set of 50 subjects for each
regimen (Figure 2) and may provide an important lead to
understanding clinical effects that differ between the two
preparations, including breast cancer. As elaborated later,
Table 3 also contains proteins that are associated with
atherogenesis.
First, consider proteins involved in the insulin growth
factor-signaling pathway. The overall pattern (Table 3) is a
greater increase in insulin growth factor-binding proteins
(IGFBP1,  IGFBP4) with E alone compared with E+P,
whereas the decrease in NOV was relatively greater with
E+P. ELISA testing produced trends in these same direc-
tions for all three proteins, but only that for IGFBP1
approached statistical significance in the independent set.
Collectively, these analyses suggest that progestin may
attenuate some of the estrogen-induced increases in IGF-
binding proteins.
It has been previously suggested that medroxyprogesterone
acetate has only a weak degree of opposition to the estrogen-
induced decrease of total IGF-1 (which is primarily of
hepatic origin), in agreement with our study findings for
IGF-1 levels [31]. However, given reduced levels of IGF-
binding proteins, it would be expected that less IGF is
bound, possibly increasing the availability of free IGF. The
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F Fi ig gu ur re e   1 1
Mean log2-transformed ratios (95% confidence interval): Intact Protein Analysis System and enzyme-linked immunosorbent assay (ELISA).
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E+P ELISA
E+P IPAS
E ELISA
E IPASIGF-signaling pathway plays a role in cell proliferation,
tissue development, and tumorigenesis. The IGF pathway
has been linked to colorectal malignancy [32,33], and serum
levels of IGF1 have been associated with colon cancer risk
[34]. Changes in the IGF pathway with E+P compared with
E-alone could potentially explain some of the differences in
the clinical outcomes. In particular, IGF-1 is a strong
mitogen, and varying levels of free IGF-1 between E+P and
E-alone treatment could help explain the increased risk of
breast cancer with E+P.
In addition to proteins related to the IGF pathway, several
other proteins of biologic interest in the context of E+P
versus E-alone effects on the serum proteome are presented
in Table 3. Expression of the α2-glycoprotein 1 zinc (AZGP1)
gene is regulated predominantly androgens and progestins
[35,36]. Our data suggest an increase in AZGP1  protein
levels with E+P and a decrease with E-alone. AZGP1 has
been identified as a potential prognostic marker for early-
stage breast cancer and a useful immunohistochemical
marker of apocrine cell differentiation in human breast
tissue [37]. Increased levels of circulating AZGP1 in E+P
compared with E-alone may be associated with increased
risk of breast cancer in the former group. Circulating levels
of extracellular matrix proteins (collagen α-1 chain (COL1A1),
lumican (LUM), and extracellular matrix protein 1 (ECM1)
may also be differentially affected by E+P compared with E-
alone, whereas MMP2, a metalloproteinase that breaks
down COL1A1, may be increased with E+P compared with E.
The extracellular matrix plays a variety of physiological
roles, many of which are related to cancer, including tumor
invasion. Changes in the extracellular matrix with E+P
compared with E-alone could also help explain the
differences in cancer risks associated with these treatments.
Several proteins listed in Table 3 have been linked to
atherogenesis, and thus may suggest avenues for exploring
mechanisms underlying a more-substantial early increase in
CHD risk with E+P than with E-alone in the randomized
trials. For example, matrix metalloproteinases (for example,
MMP2) are thought to participate in atherogenic
inflammation [38]. The role of innate immunity in athero-
genesis is less well established; PGLYRP1 participates in
recognition of bacteria by neutrophils, but is independently
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Differences of mean log2-transformed ratios (95% CI): Intact Protein Analysis System and enzyme-linked immunosorbent assay (ELISA).
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ELISAassociated with coronary artery calcification and abdominal
aortic plaque [39]. The difference in PGLYRP1 concentration
among women taking E+P versus E-alone suggests a
possible mechanistic link.
Other extracellular matrix proteins (Table 3) may also shed
light on the relation between E+P and CHD events. One such
protein, lumican (LUM), contributes to variation in proteo-
glycan composition of arterial intima by location within the
human vasculature. Enhanced deposition of lumican has
been observed in the intima of the atherosclerosis-prone
internal carotid artery compared with the internal thoracic
artery, a relatively atherosclerosis-resistant vessel [40]. The
relation between serum and tissue proteoglycan levels, the
impact of proteoglycan composition on plaque stability, and
the clinical significance of lumican all remain to be
determined.
Our proteomic comparisons (Table 3) may also provide
insight into the greater elevation in venous thromboembolic
event risk when progestin was added to conjugated estro-
gens. For example, coagulation factor V (F5) binds to multi-
merin 1 (MMFN1), with high affinity for storage in human
platelet granules, and may modulate thrombosis [41].
Some important considerations exist in assessing the effects
of estrogens and progestins broadly on the serum proteome.
The preparations considered here are conjugated equine
estrogen and medroxyprogesterone acetate. Further studies
would be needed to determine whether the changes reported
here also arise for the other estrogen (for example, 17β-
estradiol) and progesterone (norethisterone acetate or
levonorgestrel) treatments. Related to this, these substances
are taken orally, and the first-pass hepatic metabolism of
oral estrogens is known to stimulate a wide variety of proteins,
synthesized in the liver. Of the 378 proteins reported here,
73 are included in the liver-specific gene set listed in Hsiao
and colleagues [42] (Table S1 in Additional file 1). For example,
of 66 significantly upregulated proteins (FDR < 0.05), 35 are
in the liver-specific gene path, as were 28 of 71 for E-alone.
Of the proteins emphasized in the preceding discussion,
IGFBP1, AZGP1, and F5, but not others, are part of the liver-
specific list. Given that transdermal estrogen, which is being
increasingly used in clinical practice to treat menopausal
symptoms, bypasses the liver, these proteins may not be
affected when estrogen is administered transdermally.
C Co on nc cl lu us si io on ns s
In summary, E+P, like E-alone, has a profound effect on the
serum proteome and affects multiple pathways that are
relevant to observed clinical effects on cancer, cardio-
vascular disease, and fractures, among others. The addition
of 2.5 mg/d medroxyprogesterone acetate to 0.625 mg/d
conjugated equine estrogen may have an impact on the IGF
pathway proteins and may affect circulating levels of
extracellular matrix proteins (for example, MMP2) of poten-
tial relevance to the less-favorable E+P effects, compared
with those for E-alone, on breast cancer, and CHD. Similarly
the addition of medroxyprogesterone acetate may also
augment the effects of conjugated estrogens on coagulation
factors (for example, factor V), of potential relevance to a
relatively greater elevation in venous thromboembolism
with E+P. These and other leads from our proteomic study
will benefit from further testing in women who experienced
major clinical outcomes and in matched controls from the
WHI hormone therapy trials, to evaluate more directly the
potential of these protein-concentration changes to contri-
bute to a biologic explanation for observed trial-outcome
patterns.
A Ab bb br re ev vi ia at ti io on ns s
AZGP1 = α2-glycoprotein 1 zinc; CHD = coronary heart disease;
CIs = confidence intervals; COL1A1 = collagen α-1 chain; CP =
ceruloplasmin; E = conjugated equine estrogen; E+P = con-
jugated equine estrogen plus medoxyprogesterone acetate;
ECM1 = extracellular matrix protein 1; ELISA = enzyme-
linked immunosorbent assay; F5 = coagulation factor V;
FDR = false discovery rate; GnRH = gonadotropin-releasing
hormone; ICAM1 = intercellular adhesion molecule 1; IGF =
insulin-like growth factor; IGFBP = insulin-like growth
factor-binding protein; IPAS = Intact Protein Analysis
System; IPI = International Protein Index; LC-MS/MS =
liquid chromatography tandem mass spectrometry; LUM =
lumican; MMFN1 = multimerin 1; MMP2 = matrix metallo-
proteinase 2; NOV = protein NOV homologue; PGLYRP1 =
peptidoglycan recognition protein; PLA2G1B = phospholipase
A2; THBS1 = thrombospondin 1; THY1 = THY-1 membrane
glycoprotein;  VCAM1 = vascular cell adhesion protein 1;
VEGFC = vascular endothelial growth factor C; VT = venous
thromboembolism; WHI = Women’s Health Initiative.
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